SubsidieMeestersDisruptive and high accuracy test for early colorectal cancer detection in blood
AMADIX aims to enhance early colorectal cancer detection through a novel blood test, PreveCol, integrating advanced biomarkers and AI-driven risk prediction, targeting commercialization by 2032.
Projectdetails
Introduction
AMADIX is a leading molecular diagnostics company, led by Rocío Arroyo, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood.
Background on Colorectal Cancer
Colorectal cancer (CRC) is the 2nd leading cause of cancer-related deaths worldwide. Most of these cancers and deaths could have been prevented by increasing the use of recommended screening tests that detect premalignant lesions, called advanced adenomas.
Current Screening Methods
Colonoscopy is the gold standard screening method, although it is an invasive and expensive procedure.
Previous Developments
AMADIX has previously developed an innovative blood-based test for CRC diagnosis (ColoFast), based on an initial combination of cutting-edge biomarkers (micro-RNAs) and validated in over 1,000 samples.
Target Population
- Indicated to screen healthy populations from 50 to 85 years old.
- Has shown superior performance in early cancer detection compared to any of the tests commercialized.
- Demonstrates better compliance and cost-effectiveness.
Ongoing Validation
The test is currently being validated in a European prospective study with 3,100 patients (recruitment concluded), granted by SME Phase 2 with €2.8M.
Future Developments
AMADIX has identified new promising biomarkers to be incorporated into the initial signature to improve diagnostic performance.
Use of Technology
AMADIX has taken advantage of the potential of Artificial Intelligence and Big Data to identify CRC risk factors from patients’ clinical records and develop diagnostic prediction models.
Goals
Our goal is to validate this new signature, PreveCol, which is expected to be more accurate than the initial combination, based on different types of biomarkers. This will be followed by its commercialization as LDT and as an IVD kit.
Risk Factors Algorithm
In addition, a risk factors-based algorithm will be incorporated, enabling the prediction and identification of individuals with a high risk of developing CRC or premalignant polyps, even if they are younger than 50 years old, consequently improving their survival.
Financial Projections
AMADIX expects to reach accumulated revenues of €1,997M from the commercialization of PreveCol in Europe and the USA between 2023 and 2032.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.497.568 |
| Totale projectbegroting | € 3.567.954 |
Tijdlijn
| Startdatum | 1-8-2022 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ADVANCED MARKER DISCOVERY SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patientsDoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually. | EIC Accelerator | € 2.499.999 | 2024 | Details |
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancerQlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe. | EIC Accelerator | € 2.491.650 | 2024 | Details |
Pioneering diagnostics in dermatology and cancerDermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care. | EIC Accelerator | € 2.499.000 | 2022 | Details |
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanningProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly. | EIC Accelerator | € 1.987.387 | 2021 | Details |
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients
DoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually.
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer
Qlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe.
Pioneering diagnostics in dermatology and cancer
Dermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care.
Prostate cancer diagnostics using a non-invasive test based on innovative glycan-based scanning
ProSCAN aims to clinically validate a non-invasive liquid biopsy test for early-stage prostate cancer detection, potentially reducing unnecessary biopsies and associated costs significantly.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Haalbaarheidsonderzoek naar epigenetische biomarkers voor non-invasieve kankertestenEpify onderzoekt de haalbaarheid van non-invasieve epigenetische biomarkers voor vroege kankerdetectie, met focus op darmkanker. | Mkb-innovati... | € 5.349 | 2020 | Details |
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell PathwaysDevelop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes. | EIC Transition | € 2.433.125 | 2022 | Details |
Epigenetic profiling of menstrual blood for precision cancer detection and preventionThe EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers. | ERC Proof of... | € 150.000 | 2024 | Details |
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling. | Mkb-innovati... | € 20.000 | 2021 | Details |
Personalized PostYourLabLabonovum ontwikkelt met het PostYourLab platform een gepersonaliseerd gezondheidsprofiel met AI-analyse van bloedtesten, gericht op betere inzichten en efficiëntere artsconsulten. | Mkb-innovati... | € 20.000 | 2022 | Details |
Haalbaarheidsonderzoek naar epigenetische biomarkers voor non-invasieve kankertesten
Epify onderzoekt de haalbaarheid van non-invasieve epigenetische biomarkers voor vroege kankerdetectie, met focus op darmkanker.
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways
Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.
Epigenetic profiling of menstrual blood for precision cancer detection and prevention
The EpiPrecise project aims to refine a cellular deconvolution algorithm for developing novel epigenetic tests to improve cancer detection and prevention strategies, particularly for women's cancers.
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling.
Personalized PostYourLab
Labonovum ontwikkelt met het PostYourLab platform een gepersonaliseerd gezondheidsprofiel met AI-analyse van bloedtesten, gericht op betere inzichten en efficiëntere artsconsulten.